Page 2327 - Williams Hematology ( PDFDrive )

2300 Part XII: Hemostasis and Thrombosis Chapter 134: Atherothrombosis: Disease Initiation, Progression, and Treatment 2301

172. Regan ER, Aird WC: Dynamical systems approach to endothelial heterogeneity. Circ 209. Kannel WB: Overview of hemostatic factors involved in atherosclerotic cardiovascular
Res 111:110–130, 2012. disease. Lipids 40:1215–1220, 2005.
173. Cheung C, Bernardo AS, Pedersen RA, Sinha S: Directed differentiation of embryonic 210. Montoro-Garcia S, Shantsila E, Lip GY: Potential value of targeting von Willebrand fac-
origin-specific vascular smooth muscle subtypes from human pluripotent stem cells. tor in atherosclerotic cardiovascular disease. Expert Opin Ther Targets 18:43–53, 2014.
Nat Protoc 9:929–938, 2014. 211. van Galen KP, Tuinenburg A, Smeets EM, Schutgens RE: Von Willebrand factor defi-
174. Lechner D, Weltermann A: Circulating tissue factor-exposing microparticles. Thromb ciency and atherosclerosis. Blood Rev 26:189–196, 2012.
Res 122 Suppl 1:S47–S54, 2008. 212. Williams MS, Bray PF: Genetics of arterial prothrombotic risk states. Exp Biol Med
175. George FD: Microparticles in vascular diseases. Thromb Res 122 Suppl 1:S55–S9, 2008. (Maywood) 226:409–419, 2001.
176. Lacroix R, Dubois C, Leroyer AS, et al: Revisited role of microparticles in arterial and 213. Lekakis J, Bisti S, Tsougos E, et al: Platelet glycoprotein IIb HPA-3 polymorphism and
venous thrombosis. J Thromb Haemost 11 Suppl 1:24–35, 2013. acute coronary syndromes. Int J Cardiol 127:46–50, 2008.
177. Rauch U, Osende JI, Fuster V, et al: Thrombus formation on atherosclerotic plaques: 214. Weiss EJ, Bray PF, Tayback M, et al: A polymorphism of a platelet glycoprotein receptor
Pathogenesis and clinical consequences. Ann Intern Med 134:224–238, 2001. as an inherited risk factor for coronary thrombosis. N Engl J Med 334:1090–1094, 1996.
178. Ma B, Liu G, Chen X, et al: Risk of stroke in patients with patent foramen ovale: An 215. Burkhart JM, Gambaryan S, Watson SP, et al: What can proteomics tell us about plate-
updated meta-analysis of observational studies. J Stroke Cerebrovasc Dis 23:1207–1215, lets? Circ Res 114:1204–1219, 2014.
2014. 216. Berger JS, Becker RC, Kuhn C, et al: Hyperreactive platelet phenotypes: Relationship
179. Nallu K, Yang DC, Swaminathan RV, et al: Innovations in drug-eluting stents. Panminerva to altered serotonin transporter number, transport kinetics and intrinsic response to
Med 55:345–352, 2013. adrenergic co-stimulation. Thromb Haemost 109:85–92, 2013.
180. Springer J, Villa-Forte A: Thrombosis in vasculitis. Curr Opin Rheumatol 25:19–25, 217. Rauch U, Osende JI, Chesebro JH, et al: Statins and cardiovascular diseases: The multi-
2013. ple effects of lipid-lowering therapy by statins. Atherosclerosis 153:181–189, 2000.
181. Matsuura E, Kobayashi K, Lopez LR: Preventing autoimmune and infection triggered 218. Alpert JS, Thygesen K, Antman E, Bassand JP: Myocardial infarction redefined—A
atherosclerosis for an enduring healthful lifestyle. Autoimmun Rev 7:214–222, 2008. consensus document of The Joint European Society of Cardiology/American College of
182. Mok CC: Accelerated atherosclerosis, arterial thromboembolism, and preventive strat- Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol
egies in systemic lupus erythematosus. Scand J Rheumatol 35:85–95, 2006. 36:959–969, 2000.
183. Dasararaju R, Singh N, Mehta A: Heparin induced thrombocytopenia: Review. Expert 219. O’Gara PT, Kushner FG, Ascheim DD, et al: 2013 ACCF/AHA guideline for the man-
Rev Hematol 6:419–428, 2013. agement of ST-elevation myocardial infarction: Executive summary: A report of the
184. Barbui T, Finazzi G, Falanga A: Myeloproliferative neoplasms and thrombosis. Blood American College of Cardiology Foundation/American Heart Association Task Force
122:2176–2184, 2013. on Practice Guidelines: Developed in collaboration with the American College of
185. Casini A, Fontana P, Lecompte TP: Thrombotic complications of myeloproliferative Emergency Physicians and Society for Cardiovascular Angiography and Interventions.
neoplasms: Risk assessment and risk-guided management. J Thromb Haemost 11: Catheter Cardiovasc Interv 82:E1–E27, 2013.
1215–1227, 2013. 220. Wright RS, Anderson JL, Adams CD, et al: 2011 ACCF/AHA focused update incor-
186. Finazzi G, De Stefano V, Barbui T: Are MPNs vascular diseases? Curr Hematol Malig porated into the ACC/AHA 2007 Guidelines for the Management of Patients with
Rep 8:307–316, 2013. Unstable Angina/Non-ST-Elevation Myocardial Infarction: A report of the American
187. De Ceunynck K, De Meyer SF, Vanhoorelbeke K: Unwinding the von Willebrand factor College of Cardiology Foundation/American Heart Association Task Force on Practice
strings puzzle. Blood 121:270–277, 2013. Guidelines developed in collaboration with the American Academy of Family Physi-
188. Nightingale T, Cutler D: The secretion of von Willebrand factor from endothelial cells; cians, Society for Cardiovascular Angiography and Interventions, and the Society of
an increasingly complicated story. J Thromb Haemost 11 Suppl 1:192–201, 2013. Thoracic Surgeons. J Am Coll Cardiol 57:e215–e367, 2011.
189. Wong AK: Platelet biology: The role of shear. Expert Rev Hematol 6:205–212, 2013. 221. Pope JH, Ruthazer R, Beshansky JR, et al: Clinical Features of Emergency Department
190. Kulkarni S, Dopheide SM, Yap CL, et al: A revised model of platelet aggregation. J Clin Patients Presenting with Symptoms Suggestive of Acute Cardiac Ischemia: A Multicenter
Invest 105:783–791, 2000. Study. J Thromb Thrombolysis 6:63–74, 1998.
191. Wagner CT, Kroll MH, Chow TW, et al: Epinephrine and shear stress synergistically 222. American College of Emergency Physicians, Society for Cardiovascular Angiography
induce platelet aggregation via a mechanism that partially bypasses VWF-GP IB and Interventions, et al: 2013 ACCF/AHA guideline for the management of ST-elevation
interactions. Biorheology 33:209–229, 1996. myocardial infarction: A report of the American College of Cardiology Foundation/
192. Andre P, Prasad KS, Denis CV, et al: CD40L stabilizes arterial thrombi by a beta3 American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol
integrin-dependent mechanism. Nat Med 8:247–252, 2002. 61:e78–e140, 2013.
193. Winckers K, ten Cate H, Hackeng TM: The role of tissue factor pathway inhibitor in 223. Morrow DA, Braunwald E, Bonaca MP, et al: Vorapaxar in the secondary prevention of
atherosclerosis and arterial thrombosis. Blood Rev 27:119–132, 2013. atherothrombotic events. N Engl J Med 366:1404–1413, 2012.
194. Tedgui A, Mallat Z: Apoptosis as a determinant of atherothrombosis. Thromb Haemost 224. Grines CL, Browne KF, Marco J, et al: A comparison of immediate angioplasty with
86:420–426, 2001. thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in
195. Shah PK: Inflammation and plaque vulnerability. Cardiovasc Drugs Ther 23:31–40, Myocardial Infarction Study Group. N Engl J Med 328:673–679, 1993.
2009. 225. Le May MR, Davies RF, Labinaz M, et al: Hospitalization costs of primary stenting ver-
196. Kuge Y, Kume N, Ishino S, et al: Prominent lectin-like oxidized low density lipoprotein sus thrombolysis in acute myocardial infarction: Cost analysis of the Canadian STAT
(LDL) receptor-1 (LOX-1) expression in atherosclerotic lesions is associated with tis- Study. Circulation 108:2624–2630, 2003.
sue factor expression and apoptosis in hypercholesterolemic rabbits. Biol Pharm Bull 226. Pollack CV Jr, Braunwald E: 2007 Update to the ACC/AHA guidelines for the man-
31:1475–1482, 2008. agement of patients with unstable angina and non-ST-segment elevation myocardial
197. van der Stoep M, Korporaal SJ, Van Eck M: High-density lipoprotein as a modulator of infarction: Implications for emergency department practice. Ann Emerg Med 51:
platelet and coagulation responses. Cardiovasc Res 103:362–371, 2014. 591–606, 2008.
198. Endler G, Mannhalter C: Polymorphisms in coagulation factor genes and their impact 227. Califf RM, White HD, Van de Werf F, et al: One-year results from the Global Utilization
on arterial and venous thrombosis. Clin Chim Acta 330:31–55, 2003. of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I
199. Prandoni P, Bilora F, Marchiori A, et al: An association between atherosclerosis and Investigators. Circulation 94:1233–1238, 1996.
venous thrombosis. N Engl J Med 348:1435–1441, 2003. 228. Llevadot J, Giugliano RP, Antman EM: Bolus fibrinolytic therapy in acute myocardial
200. Franchini M, Mannucci PM: Association between venous and arterial thrombosis: infarction. JAMA 286:442–449, 2001.
Clinical implications. Eur J Intern Med 23:333–337, 2012. 229. Brieger DB, Mak KH, White HD, et al: Benefit of early sustained reperfusion in patients
201. Lind C, Flinterman LE, Enga KF, et al: Impact of incident venous thromboembolism on with prior myocardial infarction (the GUSTO-I trial). Global Utilization of Streptoki-
risk of arterial thrombotic diseases. Circulation 129:855–863, 2014. nase and TPA for occluded arteries. Am J Cardiol 81:282–287, 1998.
202. Celermajer DS, Sorensen KE, Spiegelhalter DJ, et al: Aging is associated with endothe- 230. Pollack CV Jr, Antman EM, Hollander JE: 2007 Focused update to the ACC/AHA
lial dysfunction in healthy men years before the age-related decline in women. J Am guidelines for the management of patients with ST-segment elevation myocardial
Coll Cardiol 24:471–476, 1994. infarction: Implications for emergency department practice. Ann Emerg Med 52:
203. Franchini M, Targher G, Montagnana M, Lippi G: The metabolic syndrome and the risk 344–355.e1, 2008.
of arterial and venous thrombosis. Thromb Res 122:727–735, 2008. 231. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocar-
204. Lowe GD: Common risk factors for both arterial and venous thrombosis. Br J Haematol dial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Lancet
140:488–495, 2008. 350:389–396, 1997.
205. Ye Z, Liu EH, Higgins JP, et al: Seven haemostatic gene polymorphisms in coronary 232. Stone NJ, Robinson JG, Lichtenstein AH, et al: 2013 ACC/AHA guideline on the treat-
disease: Meta-analysis of 66,155 cases and 91,307 controls. Lancet 367:651–658, 2006. ment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A
206. Kamphuisen PW, ten Cate H: Cardiovascular risk in patients with hemophilia. Blood report of the American College of Cardiology/American Heart Association Task Force
123:1297–1301, 2014. on Practice Guidelines. J Am Coll Cardiol 63:2889–2934, 2014.
207. Sramek A, Reiber JH, Gerrits WB, Rosendaal FR: Decreased coagulability has no clin- 233. Cannon CP, Murphy SA, Braunwald E: Intensive lipid lowering with atorvastatin in
ically relevant effect on atherogenesis: Observations in individuals with a hereditary coronary disease. N Engl J Med 353:93–96; author reply 93–96, 2005.
bleeding tendency. Circulation 104:762–767, 2001. 234. Antithrombotic Trialists’ Collaboration: Collaborative meta-analysis of randomised
208. Haverkate F: Levels of haemostatic factors, arteriosclerosis and cardiovascular disease. trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke
Vascul Pharmacol 39:109–112, 2002. in high risk patients. BMJ 324:71–86, 2002.

Kaushansky_chapter 134_p2281-2302.indd 2301 17/09/15 3:50 pm